Krystal Biotech, Inc.
KRYS
$256.33
$6.172.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 107.11M | 97.80M | 96.04M | 88.18M | 91.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 107.11M | 97.80M | 96.04M | 88.18M | 91.14M |
| Cost of Revenue | 6.59M | 4.26M | 7.17M | 5.03M | 4.95M |
| Gross Profit | 100.51M | 93.54M | 88.88M | 83.16M | 86.19M |
| SG&A Expenses | 41.45M | 37.58M | 35.16M | 32.72M | 31.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.84M | 56.43M | 56.74M | 52.01M | 49.76M |
| Operating Income | 44.27M | 41.37M | 39.31M | 36.18M | 41.38M |
| Income Before Tax | 51.13M | 47.97M | 46.78M | 43.60M | 48.61M |
| Income Tax Expenses | -269.00K | -31.40M | 8.44M | 7.86M | 3.13M |
| Earnings from Continuing Operations | 51.40M | 79.37M | 38.33M | 35.73M | 45.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.40M | 79.37M | 38.33M | 35.73M | 45.48M |
| EBIT | 44.27M | 41.37M | 39.31M | 36.18M | 41.38M |
| EBITDA | 44.83M | 41.68M | 39.62M | 36.62M | 41.64M |
| EPS Basic | 1.77 | 2.74 | 1.33 | 1.24 | 1.58 |
| Normalized Basic EPS | 1.10 | 1.04 | 1.01 | 0.95 | 1.06 |
| EPS Diluted | 1.70 | 2.66 | 1.29 | 1.20 | 1.53 |
| Normalized Diluted EPS | 1.06 | 1.00 | 0.98 | 0.91 | 1.02 |
| Average Basic Shares Outstanding | 29.09M | 28.95M | 28.91M | 28.82M | 28.76M |
| Average Diluted Shares Outstanding | 30.25M | 29.83M | 29.75M | 29.87M | 29.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |